Roles of mast cells in rheumatoid arthritis

Hong Ki Min¹, Kyoung-Woon Kim², Sang-Heon Lee³, and Hae-Rim Kim³

¹Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Seoul; ²Conversant Research Consortium in Immunologic Disease, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul; ³Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea

Rheumatoid arthritis (RA) is a chronic autoimmune inflammatory arthritis, and the complex interaction and activation of innate and adaptive immune cells are involved in RA pathogenesis. Mast cells (MCs) are one of the tissue-resident innate immune cells, and they contribute to RA pathogenesis. In the present review, the evidence of the pathologic role of MC in RA is discussed based on human and animal data. In addition, the potential role of MC in RA pathogenesis and the research area that should be focused on in the future are suggested.

Keywords: Arthritis, rheumatoid; Mast cell; Etiology

INTRODUCTION

Rheumatoid arthritis (RA) is a systemic autoimmune arthritis that affects small peripheral joints. Inflammatory changes of synovium (synovitis) is a cornerstone characteristic of RA, and synovial hyperplasia with the infiltration of synovial membrane with various immune cells, T cells, B cells, and innate immune cells such as mast cells (MCs), have been observed in RA synovitis [1]. In RA, uncontrolled synovitis leads to the progressive destruction of joint structures including cartilage and bone, and thus, prevention of structural damage in the joints is one of the most important treatment targets. Many synthetic disease-modifying antirheumatic drugs (DMARDs) have therapeutic effects, and nowadays, several biologic DMARDs targeting monocytes, T cells, and B cells and oral small molecule inhibitors such as Janus kinase inhibitors are used in managing RA patients who do not respond to synthetic DMARDs. Despite novel therapeutic options, biologic DMARDs, and oral small molecule inhibitors, some patients still do not respond to these therapies. Furthermore, the prevention of RA in preclinical or early stages of RA has been attempted, and research on this theme has been ongoing [2,3]. However, administering synthetic or biologic DMARDs in the early phase of RA does not have dramatic effects on preventing RA.

Post-translational modifications such as citrullination and carbamylation induce aberrant immune response via antigen presenting cells (APCs) and promote autoantibody production [3]. The RA patients that have autoantibodies, immunoglobulin M (IgM) to Fc portion of IgG (rheumatoid factor), anti-citrullinated protein antibody (ACPA), or anti-carbamylated protein antibody, are called seropositive RA patients, and these autoantibodies play a critical role on RA pathogenesis [4]. Thus, RA was believed to be an autoimmune disease caused by aberrant adaptive immune response initiated by autoantibody production [5]. However, the pathologic role of MCs in RA emerged in a study that showed
the histologic finding of synovium, which indicated an increased proportion of MCs in RA patients than those in healthy control [6]. Furthermore, the MCs interact with various immune cells and show the potential pathologic role of MCs in various autoimmune disorders [7]. Recently, the analysis of early stage RA synovium showed different phenotypes of synovitis according to the density of MC infiltration, thereby supporting that the underlying mechanisms of RA pathogenesis are heterogenic and MCs may play an important role in RA pathogenesis [8].

RA is divided into several stages: autoantibodies production, subclinical synovitis, and clinical established RA [9]. Immune response is initiated by local innate immune cells that are exposed to external antigens or autoantigens (such as MCs, macrophages, dendritic cells, and natural killer [NK] cells) in the case of autoimmune diseases [10]. The APCs then interact and activate the immune cells of the adaptive immune system such as B cells and CD4⁺/CD8⁺ T cells. Thus, the initial immune responses are dominant in local innate immune cells. MCs are one of the innate immune cells that are site specific and intimate with the external environment [11]. The MCs respond to the antigen before the other immune cells, and they secrete various chemokines, recruit other immune cells, and cause local tissue inflammation, edema, neovascularization, and tissue remodeling [11]. Furthermore, RA synovium shows increased vascularity and MC population than in a healthy synovium, which indicates the potential increase in the interaction between MCs and autoantigens in the early phase of autoimmune diseases. Based on previous results that showed an increased MC population in RA synovium, research investigating the role of MC in RA pathogenesis is ongoing. This review focuses on the pathologic roles of MC in RA and potential therapeutic alternatives for targeting MCs.

**MAST CELLS IN RHEUMATOID ARTHRITIS PATHOGENESIS**

**Overall characteristics of MC**

MCs were first found by Friedrich von Recklinghausen in 1863 and well defined by Paul Ehrlich in 1878. An MC is a tissue-resident cell originated from a myeloid stem cell [11]. The MC progenitors are derived from bone marrow, and they circulate in the blood stream. Settled MC progenitors completely differentiate into MCs in the peripheral tissues, and they typically contain preformed mediators such as histamine, proteases, and heparin [12]. Further, MCs have the high-affinity IgE receptor (FcεRI), and they act as the major immune cells in allergic reactions causing an immediate release of the preformed mediators [13]. Allergic and autoimmune diseases have similar characteristics in that they are results of aberrant and hyperactive immune response to allergens or autoantigens, which are not immunogenic in a normal immune system. Furthermore, many evidences indicate the pathologic role of MCs in autoimmune diseases including RA [7], and previous studies have shown an increase in the population of MCs in RA synovium [1,6].

**MC in RA synovium**

MCs exist in normal synovium; their population increases in RA synovium compared to that in healthy control [6]. The MC count correlates with clinical synovitis, but not with erythrocyte sedimentation rate (ESR) [6]. In another study, active RA shows higher MC infiltration than end-stage diseases [14]. The MC count shows strong correlation with lymphocyte count in RA synovium, and intra-articular steroid injection reduces the MC count in the RA synovium [15]. The morphology and ability of the histamine secretion of synovial MCs are similar to that of the MC from the lung and intestine, which indicates that synovial MC is not significantly different from the MC of other organs [16]. The MCs from RA synovium differ from those of the osteoarthritis (OA) synovium in that the C5a receptor (CD88) expression is solely present in RA synovial MC [17]. Stem cell factor (SCF), a ligand of c-kit, and c-kit positive MC hyperplasia are correlated with local inflammation in the synovium; however, this response occurs in not only RA, but also in traumatic arthritis or OA [18]. The RA synovial fluid shows elevated chemotaxin for the MC, SCF, and transforming growth factor-β (TGF-β) [19]. The MCs are divided based on their phenotypes according to expressing proteases, tryptase, and chymase. MC_T only presents tryptase, whereas MC_C presents both tryptase and chymase. There is a higher infiltration rate of MCs in fibrous synovial tissues (2.8%) than in cellular synovial tissues (1.18%), and extracellular
tryptase (which indicate the activation of MC) is associated with localized tissue edema and stromal matrix disruption [20]. In this study, MCγε is more prominent than MCαε in RA synovium (MCγε:MCαε ratio, 8:1) [20]. MCγε and MCT are all expanded in the superficial and deeper layers of RA synovium than that in the healthy synovium. MCT is dominant in the superficial layer, which is the area close to the inflammatory cell infiltration, whereas MCγε is located in a deeper layer, which is the area approximately close to the cellular, dense, fibrous connective tissues [21]. Furthermore, the total MCTC correlates significantly with the swollen joint counts, and the superficial MCγε correlates with the disease severity index [21]. In early RA (mean duration 8 months), MCε are dominant and they significantly correlate with the inflammation index [22]. These results suggest that MCT and MCγε might have different roles, such as MCT for the early inflammation response and MCTC for the late destructive change of RA [21,22]. All previous studies have some limitations in that most synovia are obtained from knee joints, whereas RA affects small joints, and the disease duration is relatively long.

Recently, utilizing ultrasonography (US) for the evaluation of arthritis, some studies based on US-guided synovial biopsy have been introduced. Synovial tissues from reactivated RA patients show increased MCs and B cells than those in RA patients who maintain remission, which indicates the potential role of MCs in disease reactivation [23]. In treatment-naïve RA patients, early RA can be divided into three subgroups: fibroid (low MC density), myeloid (medium MC density), and lymphoid (high MC density) [8]. MC density positively correlates with acute reactants (C-reactive protein, ESR) and disease activity score (DAS-28) [8]. The ratio of MCT and MCγε is different based on the subtypes (MCγε:MCαε ratio in fibroid 1:6, lymphoid 1:2), and MCT is significantly correlated with synovial inflammation, indicating the potential role of MCT in the acute inflammation of RA [8,22].

**ACTIVATION OF MAST CELL IN RHEUMATOID ARTHRITIS**

MC is activated via various pathways, and the activated MC secretes mediators, stimulates other immune cells and local synoviocytes, and recruits circulating inflammatory cells into the RA synovium. Preformed mediators (histamine, heparin, and proteases) are excreted from MCs by immediate immune response; however, MCs are also capable of producing and excreting various lipid-derived mediators, cytokines, and chemokines [24]. The aforementioned de novo production is mediated by several immunologic stimulations.

MCs are activated by various stimulants such as the immunoglobulins-Fc receptor interaction, toll-like receptors (TLRs), chemokines, cytokines, pathogen-associated molecular patterns (PAMP), or neuropeptides [11]. The MCs are mainly activated via IgE stimulations, and MCs from RA are also stimulated by the IgE-FcεR interaction [16,17]. The MCs possess not only FcεR, but also Fc gamma receptor (FcyRI), and therefore, they can be activated even with IgG, which is the major immunoglobulin produced under chronic inflammatory status such as RA.

**Immunoglobulin-FcR interaction**

Conventionally, MC activation is mediated via IgE-FcεR interaction in in vitro experiments. Histamine, tryptase, proinflammatory cytokines (IL-1, tumor necrosis factor-α [TNF-α]), and lipid-derived mediators (prostaglandin D2 [PGD2]/prostaglandin E2 [PGE2] and leukotriene C4) secreted from RA synovial MC are augmented via anti-IgE stimulation [16,17,24-26]. Human synovial MC presents FcRI, Fc-gamma receptor type 1 (FcyRI), and Fc-gamma receptor type 2 receptor (FcyRII), but not Fc-gamma type 3 receptor (FcyRIII) [26], and the RA synovial MCs specifically overexpresses Fc-gamma type 2 receptor A (FcyRIIA) [27]. In human synovial MCs, FcγRI-IgG mediates PGD2 and TNF-α production, whereas histamine production is mediated via both FcγRI and FcγRIIA [26]. Furthermore, ACPA-citrulline peptide immune complex activates MC and promotes IL-8 secretion via FcγRIIA [27,28].

**TLR ligands**

TLRs are expressed in various immune cells, and they play a critical role in eliminating exogenous pathogens by recognizing PAMP. Endogenous TLR ligands, such as heat shock protein 70 (HSP70), are increased in the RA synovial fluid, and the TLR4 ligands, tenasin-C, and extra domain A of fibronectin, induce joint inflam-
mation in a mice model [29-31]. TLR1-TLR9 are expressed in MC, and TLR2, TLR4, and TLR8 are capable of inducing TNF-α production [27]. MC activation via HSP70-TLR4 interaction is synergized when ACPA immune complex-FcγRIIA co-exists [27].

MC activation via neuropeptides and cytokines

Substance P—one of the neuropeptides—induces MC activation via Mas-related X2 expression in RA synovium [32]. Stimulation with IL-33—an IL-1 superfamily—is critical in the induction of collagen-induced arthritis (CIA) and autoantibody-induced arthritis (AIA) animal models via MC activation [33,34]. In human RA synovium, IL-33 and the ACPA immune complex also induce MC activation, and the combination of IL-33 and immune complex increases inflammation via the upregulation of IL-8 and TNF-α production [28,35]. Simultaneously, this mediates IL-10/histamine secretion and induces an immune modulatory effect by suppressing monocyte activation [28]. Furthermore, IL-33 stimulated MC overexpresses FcγRIIA, which can augment ACPA mediated MC activation [28].

EFFECTOR ROLES OF ACTIVATED MAST CELL

Roles of preformed mediators of MCs in RA

Histamine is a major preformed mediator in MCs, and it increases vascular permeability and recruits neutrophils in RA animal models [36]. FcγR-expressing cells mediate histamine-induced vascular leaks, although the exact cell type of FcγR-expressing cells is unknown; the candidate cell is an MC [36]. In RA synovium, histamine is released by the stimulation of anti-IgE, SCF, and C5a [16,17]. MCs extracted from an active RA patient’s synovium secrete greater histamine than that from an inactive RA patient’s synovium under stimulation with anti-IgE; histamine content decreases in MCs in DMARD-treated RA patients [37]. Histamine binds with four receptors (histamine receptors 1–4 [H1R–H4R]), and among them, H4R plays a crucial role in arthritis development in K/BxN RA mice model [38]. In terms of osteoclasts, the main effector cells of the bone erosion of RA, histamine and H4R, promote receptor activator of nuclear factor-κB ligand (RANKL) expression and osteoclastogenesis [39]. In a fracture and osteoporosis mice model, the granular mediators of MCs, especially histamine, are critical for osteoclastogenesis [40].

MCγ7 and MCγc are increased in RA synovium. Tryptase excreted from RA synovial MC enhances collagen degradation by activating latent synovial collagenase [41]. The mouse model of RA shows an increased level of MC restricted mast cell protease 6 (MCP-6) (corresponding to human tryptase β)/heparin complexes in synovium, and these complex induces inflammatory arthritis and even bone loss caused by an increase in the neutrophil chemotactic factors with the loss of cartilage-derived aggrecan [42,43]. Tryptase inhibition in the mouse model reduces late phase joint edema, chemokine (C-X-C motif) ligand 1 (CXCL1), and IL-6 production; however, the overall joint destruction is not attenuated [44]. Another protease, chymase, is also elevated in RA synovial fluid than OA, and it proposes to mediate synovitis by producing the active form of chemerin (chem 156F), a chemotactant for NK cells, macrophages, and dendritic cells [45]. In the RA rat model, synovial chymase from RA rat was found to promote the proliferation of synovial fibroblasts and the expression of matrix metalloproteinase 9 (MMP-9), focal adhesion kinase (FAK), and p21, which are markers for cell migration and adhesion [46]. Chymase induces “tumor-like” characters of synovial fibroblasts in RA [46]. Chymase and tryptase are well known angiogenic factors in tumorous conditions [47]. In addition to protease, MC secretes various proangiogenetic factors, vascular endothelial growth factors, basic fibroblast growth factors, TGF-β, TNF-α, and IL-8 [48]. Synovial fibroblasts of RA have “tumor-like” characteristics—invasion, destructing adjacent tissues, and increasing vascularity by forming pannus—and therefore, suppressing the “tumor-like” features of RA synovium by modulating MCs containing proteases, chymase, and tryptase, is considered a potential therapeutic target.

Lipid derivatives and proinflammatory cytokine from MC in RA

Lipid derivatives from arachidonic acid are increased in RA synovium and play an inflammatory role; drug targeting enzymes of arachidonic acid metabolism—cyclooxygenase inhibitors—are useful for controlling the pain caused in arthritis [49]. Proinflammatory cytokines, IL-1β, IL-6, IL-17, and TNF-α, are elevated in
RA patients systemically and at inflamed synovium [50]. Several biologic DMARDs have therapeutic effects induced by blocking these proinflammatory cytokines [4].

The metabolites of arachidonic acid depend on the enzymes. Lipooxygenase mediates the production of leukotrienes, and cyclooxygenases mediate prostaglandins and thromboxane production [49]. Leukotriene B4 (LTB4), PGE2, and prostaglandin I2 (PGI2) induce an inflammatory response in RA pathogenesis [49]. The genetic deficiency for the receptor of LTB4, leukotriene B4 receptor 1 (BLT1), and BLT2, prevents arthritis in mouse models [51]. Although MC is the major source of LTB4 in IgE-mediated allergic response [52], the role of MC-derived LTB4 in RA inflammatory response is not elucidated. Under stimulation with rabbit IgG anti-human IgE on RA synovium, PGE2 is overexpressed [25]. PGD2 is released from RA synovium-derived MC through FcγRI activation [26]. The urinary metabolite of PGD2, tetranor prostaglandin D metabolite (T-PGDM), in RA patients are higher than those in the control, and it is suggested as a biomarker of MC activation in RA patients [53].

Several proinflammatory cytokines, IL-1, IL-6, IL-17, and TNF-α, play critical roles in RA pathogenesis, and the targeted therapies for these cytokines show dramatic therapeutic effects on RA [4]. The secretion of TNF-α and IL-1β from RA synovial MC significantly is increased by stimulation with rabbit IgG antibodies for human IgE [54]. There is increased TNF-α production of cultured synovium-derived MCs via an IgG receptor, FcγRI [26]. In AIA model, MCs are critical for the initiation of arthritis via the production of IL-1, and MCs are activated via FcγRIII [55]. The major source of IL-17A in RA synovium is MCs, and not CD4+ T cells [56]. However, another study shows that there is no difference in the IL-17A positive synovial MCs in RA and OA [57]. In the K/BxN serum transfer RA model, c-Jun N-terminal kinase (JNK) 1 controls MC activation and FcγRII mediated activation [27]. The aforementioned interaction of MC and B cells occur in ectopic lymphoid tissue of synovium in a contact-mediated manner [8]. These indirect influences of MCs on localized or circulating cells are another important pathologic role in RA [62].

**CELLULAR INTERACTION OF MAST CELL WITH OTHER INFLAMMATORY CELLS AND LOCAL SYNOVIOCYTES**

**Cell interactions with MCs in RA**

MCs are involved in RA pathogenesis via direct roles such as secreting preformed mediators and newly synthesized inflammatory mediators; however, MCs also influence other immune cells or local synoviocytes. In RA synovium, MCs closely contact CD3+ T cells, CD14+ monocytes, and CD20+ B cells [28]. These indirect influences of MCs on localized or circulating cells are another important pathologic role in RA [62].

**MC-lymphocytes interactions**

B and T cells are major immune cells of the adaptive immune system, and they play crucial roles in RA pathogenesis. Interactions between MC and these lymphocytes increase the adaptive immune response in RA pathogenesis. The in vitro experiment of mice shows that MCs induce naïve and B cell receptors that stimulate B cell proliferation and activation by cell-to-cell contact; further, it promotes immunoglobulin secretion [63]. Synovial MC from treatment naïve RA patients enhances B cell activation, differentiation, and ACAP production [8]. The aforementioned interaction of MC and B cells occur in ectopic lymphoid tissue of synovium in a contact-mediated manner [8]. These findings are worthy in that MC plays a critical role in autoantibody production in RA patients.

T cells are usually stimulated by APCs, such as dendritic cells, macrophage, and B cells. The T cell receptor (TCR) recognizes the antigen presented in APCs, and it becomes active. Stimulated MC expresses MHC
molecules and acts as APC to CD4+ and CD8+ T cells [64-66]. MC can skew CD4+ T cell into a specific subtype of CD4+ T cell in a cell-to-cell contact manner [65,67]. The MCs can recruit effector CD8+ T cell via excreting LTB4 [68], and it also activates T cells by TNF-a production [69]. However, direct evidences supporting the importance of MC-T cell interaction in RA pathogenesis is yet to be proved.

**Synoviocyte stimulation via MC activation**

Cartilage and bone erosion with pannus formation are classical changes in advanced RA, and this is mediated by synovial fibroblasts. Tryptase from MC induces collagen degradation by transforming RA synoviocyte procollagenase into the active form via MMP-3 activation [41,70]. In addition, activated MCs are localized to the sites of cartilage erosion and matrix disruption in RA synovial species indicating that the activation of MCs is involved in the process of erosion [20,71]. Tryptase-β1/heparin complex, one of the MC mediators, induces IL-8 expression in synoviocyte and promotes neutrophil recruitment [42]. Tryptase from MCs exert an anti-apoptotic effect on RA fibroblast-like synoviocytes (FLS) via rho-mediated signaling [72]. In the RA rat model, chymase from MC induces FLS proliferation and MMP-9/IL-6 expression, and this response is amplified in RA synoviocyte than that in normal synoviocyte [46]. This suggests that RA synoviocytes may have an augmented response to MC mediators compared to normal synoviocytes.

**IMMUNOMODULATORY EFFECTS OF MAST CELL IN RHEUMATOID ARTHRITIS**

The MC is a tunable cell and can also provoke anti-inflammatory immune response under certain circumstances [73]. In RA synovium, IL-33 induces MC activation and suppress monocytes via IL-10 and histamine [28]. MC specific gene expressions in RA synovium demonstrate inverse correlation with disease activity, and IL-33 mRNA levels inversely correlate with the mRNA levels of proinflammatory markers [28]. Serum and synovial mRNA levels of tryptase also inversely correlate with C-reactive protein levels in treatment naive early RA patients [74,75]. The aforementioned results support that MCs may play both proinflammatory and anti-inflammatory roles in RA; however, the specific roles of MC mediators and MC responses in the specific stage of RA should be evaluated.

**ROLE OF MAST CELL IN THE INDUCTION OF ARTHRITIS IN RHEUMATOID ARTHRITIS ANIMAL MODELS: CONTRADICTORY RESULTS**

Evidences supporting pathologic roles of MC in RA: pros

Most animal models used to reveal the pathologic role of MC in RA are provoked via a conditional knockout of specific genes. Knockout mice of MC related to protease chymase, and tryptase/heparin complex genes demonstrate the suppression of arthritis in MC protease deficient mice [42,43,76]. CIA induction in A20 deficient mice, MC hyperactivity via ablating nuclear factor-κB negative feedback regulator, arthritis incidence and severity are more severe than that in the wild type control, which supports the pathologic role of MCs in RA [77]. Another approach is to eliminate MCs from mice by modulating SCF and c-kit related genes. SCF deficient (Kit Sl DSl) or SCF receptor (c-kit) deficient mice (Kit W Kit W-v) have resistance to arthritis in K/BxN serum transfer model [78]. This Kit W Kit W-v mice restore susceptibility to develop arthritis via intraperitoneal or intra-articular injection of MCs [79]. Mutation on c-kit signaling related genes can cause several immune and non-immune abnormalities beyond MC deficiency because it is not uniquely expressed in MCs. Diphteria toxin (DT) induced MC depletion is an alternative mice model for MC deficiency [80]. Mcpt5-Cre iDTR mice, which induces MC deficiency without altering c-kit signaling, reveals that MC deficiency without altering c-kit signaling, reveals that MC deficiency reduces arthritis in antigen-induced arthritis mice (T cell dependent model), whereas MC is redundant in the pathogenesis of antibody-induced arthritis mice (T cell independent model) [81]. By using other DT induced MC depletion model, depleting MCs in established arthritis do not influence on arthritis progression, whereas early depletion of MC reduces clinical arthritis score in CIA model [59]. These findings support that MC may possess different importance according to disease stages, essentially in the early stage (prior to adaptive immune
system activation and auto-antibodies production), but it is dispensable in the late stage of RA pathogenesis.

**Redundant role of MC in RA pathogenesis: cons**

Another c-kit mutation induced MC deficiency model, Kit\(^W^{-sh}\)/Kit\(^W^{-sh}\) mice, is susceptible for arthritis both in antibody mediated and antigen mediated models [82,83]. Kit\(^W\)/Kit\(^W\)-v mice and Kit\(^W\)/Kit\(^W\)-sh mice have differences in that Kit\(^W\)/Kit\(^W\)-v mice have more clinical manifestations other than MC deficiency [84]. Importantly, Kit\(^W\)/Kit\(^W\)-v mice show neutropenia and attenuated response to lipopolysaccharide stimulation, whereas Kit\(^W\)/Kit\(^W\)-sh mice have neutrophilia [82]. The baseline neutrophilia of Kit\(^W\)/Kit\(^W\)-v mice may contribute to the susceptibility of arthritis induction, and this makes MC dispensable in the Kit\(^W\)/Kit\(^W\)-sh mice arthritis model. In Cpa3\(^{Cre/+}\) mice, MC depletion is achieved by Cre-recombinase, and arthritis can be induced by K/BxN serum transfer [85]. Cpa3\(^{Cre/+}\) mice have a normal immune system except MC deficiency, and this selective MC deficiency is different from that in c-kit signal mutant mice. These contradictory results of MC roles in animal models should be interpreted carefully by considering background mutation combined with other immune abnormalities. The roles of MC in RA pathogenesis proved in human and animal RA data are summarized in Table 1.

**CLINICAL IMPLICATION OF MAST CELL IN RHEUMATOID ARTHRITIS**

Early RA is divided into three histological types according to synovial MC counts: fibroid, myeloid, and lymphoid types [8]. RA is heterogeneous disease, and each RA patient has different clinical manifestation, drug response, and disease course. Furthermore, applying “precision medicine” to RA patients has emerged [86], and the personalized treatment strategy aims to achieve early remission and cease structural damage of RA. Categorization of synovial pathology according to MC population suggests potential to establish “precision medicine” to RA.

In pharmacologic intervention research, imatinib, which is used in Philadelphia chromosome positive leukemia and inhibits c-kit tyrosine kinase, induces MC apoptosis and suppresses TNF-\(\alpha\) production [60]. In animal model, applying MC stabilizer, cromolyn, salbutamol, and tranilast, suppress proinflammatory cytokine production and structural damages [61,79]. When comprehensively consider these experimental intervention and histologic type of RA synovium according to MC population, MC suppressor or stabilizer could promise adjuvant therapeutic effects for RA patients with MC rich in synovium (lymphoid type).

**FUTURE RESEARCH AGENDA**

Although previous studies demonstrated many evidences that showed pathologic roles of MC in RA pathogenesis, there were still many unrevealed roles of MCs. First, MCs secrete chemokines and derive infiltration of various immune cells such as neutrophils, T cells, and macrophages [87]; however, the direct evidence of these functions in RA is yet to be fully demonstrated. Further studies focusing on the chemoattractive function of MCs need to be performed. Second, MCs stimulate B cell responses in RA synovium [8], but MCs also stimulate various other immune cells, such as T cells, via acting as APCs [64,66,88]. However, the relevant roles of MCs in stimulating other immune cells are poorly understood in RA, except for B cells. Third, the influence of MCs in the angiogenesis of RA synovium needs to be studied. Several mediators, such as tryptase and chymase, promote neovascularization in various cancers [47], and these might have a role on forming “tumor-like” aggressive characteristics of RA synovium. Finally, ablating or suppressing MCs at the preclinical or early phase of RA might be an effective treatment choice in the future because several evidences support that MCs are critical in early RA pathogenesis. Several trials are performed to suppress MCs in RA synovium or RA mice [60,61,79], and these showed the potential of the therapeutic role of MC suppression in RA treatment. Table 2 summarizes the potential roles of MCs in RA pathogenesis and future research objectives that should be proved in RA.

**CONCLUSIONS**

The network of innate and adaptive immune systems...
Table 1. Evidences from human and animal RA data: roles of MCs in RA pathogenesis

| Findings | Data source | Reference |
|----------|-------------|-----------|
| **Synovitis** | Correlation between clinical synovitis and MCs counts in RA synovium | Human | [6] |
| More synovial MCs in active disease than burnt out disease | Human | [14] |
| Treatment (intra-articular steroid injection) decreases MC population | Human | [15] |
| c-kit/SCF positive MC hyperplasia correlates with local inflammation | Human | [18] |
| **Erosion** | Local accumulation of MCs is closely located with cartilage erosion | Human | [20,71] |
| Tryptase from MC activates collagenase | Human | [41,76] |
| **Chemoattractant** | Chymase produces active form of chemerin | Human | [45] |
| Histamine | Histamine secretion is elevated in RA synovium by MC stimulation/MC from active RA patients have greater capacity to secrete histamine | Human | [16,17,28,37] |
| **Lipid derivatives** | Increased PGE2 and PGD2 secretion via MC stimulation | Human | [25,26] |
| **Proinflammatory cytokines** | Secretion of TNF-α via MC stimulation | Human | [26,27,35,54,60] |
| Secretion of IL-1β via MC stimulation | Human | [54] |
| MC is the major source of IL-17A in RA synovium | Human | [56] |
| IL-8, neutrophil chemotactic factor, is increased via MC activation | Human | [27,28,35] |
| **B cell and autoantibody** | B cell proliferation, activation, and ACPA production are upregulated by MC via cell to cell contact | Human | [8] |
| **Experimental arthritis models** | Knock out of chymase or tryptase/heparin complex suppresses arthritis | Mice | [42,43,76] |
| CIA with MC hyperactivity induced by Azo deficient has higher arthritis incidence and arthritis severity score than control mice | Mice | [77] |
| SCF deficient (Kitl+/Kitl-/-) and SCF receptor (c-kit) deficient mice (Kitw+/Kitw-/-) have resistance to arthritis induction in K/BxN serum transfer model and restore arthritis induction by intra-articular or intraperitoneal engraftment of MC | Mice | [78,79] |
| MC depletion mice via diphtheria toxin injection shows resistance to arthritis when arthritis is induced by collagen antigen (T cell dependent manner), especially in preclinical stage | Mice | [59,81] |
| **Monocyte inactivation** | Activated MC suppresses TNF-α production of CD14+ monocyte via IL-10 and histamine | Human | [28] |
| **Inverse correlation of serum/ synovial tryptase with CRP** | Serum tryptase level and synovial tryptase mRNA level, marker for MC activation, negatively correlate with serum CRP level of early RA patients | Human | [74,75] |

https://doi.org/10.3904/kjim.2019.271
plays critical roles in RA pathogenesis. The MCs belong to innate immune cells, but they also influence the adaptive immune system in various ways, such as by cell-to-cell contact or secreting cytokines and chemokines. Many evidences support the pathologic roles of MC in RA, especially recent US-guided synovial biopsy studies, which showed the correlation between disease activity and MC infiltration [8,23]. These studies suggest that MC might play a critical role in the onset of RA via interaction with B cells. Therefore, focusing on the role of MCs and modifying MCs in early or preclinical phases of RA might provide new insight into RA pathogenesis and novel treatment strategies.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This research was supported by a grant of the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology, Republic of Korea (NRF-2018R1D1A1A02050982).
REFERENCES

1. Pitzalis C, Kelly S, Humby F. New learnings on the pathophysiology of RA from synovial biopsies. Curr Opin Rheumatol 2013;25:334-344.
2. Deane KD, Striebich CC, Holers VM. Editorial: prevention of rheumatoid arthritis: now is the time, but how to proceed? Arthritis Rheumatol 2017;69:873-877.
3. Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.
4. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360-1372.
5. Malmstrom V, Catrina AI, Klareskog L. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting. Nat Rev Immunol 2017;17:60-75.
6. Crisp AJ, Chapman CM, Kirkham SE, Schiller AL, Krane SM. Articular mastocytosis in rheumatoid arthritis. Arthritis Rheum 1984;27:845-851.
7. Xu Y, Chen G. Mast cell and autoimmune diseases. Mediators Inflamm 2015:2015:246126.
8. Rivellese F, Mauro D, Nerviani A, et al. Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Ann Rheum Dis 2018;77:1773-1777.
9. van de Sande MG, de Hair MJ, van der Leij C, et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011;70:772-777.
10. Waldner H. The role of innate immune responses in autoimmune disease development. Autoimmun Rev 2009;8:400-404.
11. Krystel-Whittemore M, Dileepan KN, Wood JG. Mast cell: a multi-functional master cell. Front Immunol 2016;6:620.
12. Dahlin JS, Hallgren J. Mast cell progenitors: origin, development and migration to tissues. Front Immunol 2016;6:620.
13. Amin K. The role of mast cells in allergic inflammation. Respir Med 2012;106:99-14.
14. Godfrey HP, Ilaridi C, Engber W, Graziano FM. Quantitation of human synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis Rheum 1984;27:852-866.
15. Malone DG, Wilder RL, Saavedra-Delgado AM, Metcalf DD. Mast cell numbers in rheumatoid synovial tissues. Correlations with quantitative measures of lymphocytic infiltration and modulation by anti-inflammatory therapy. Arthritis Rheum 1987;30:130-137.
16. Kopicky-Burd JA, Kagey-Sobotka A, Peters SP, et al. Characterization of human synovial mast cells. J Rheumatol 1988;15:1326-1333.
17. Kiener HP, Baghestanian M, Dominkus M, et al. Expression of the C5a receptor (CD88) on synovial mast cells in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:233-245.
18. Ceposin A, Konttinen YT, Takagi M, et al. Expression of stem cell factor (SCF) and SCF receptor (c-kit) in synovial membrane in arthritis: correlation with synovial mast cell hyperplasia and inflammation. J Rheumatol 1998;25:304-314.
19. Olsson N, Ulfgren AK, Nilsson G. Demonstration of mast cell chemotactic activity in synovial fluid from rheumatoid patients. Ann Rheum Dise 2001;60:187-193.
20. Tetlow LC, Woolley DE. Distribution, activation and tryptase/chymase phenotype of mast cells in the rheumatoid lesion. Ann Rheum Dis 1995;54:49-55.
21. Gotis-Graham I, McNeil HP. Mast cell responses in rheumatoid synovium. Association of the MCTC subset with matrix turnover and clinical progression. Arthritis Rheum 1997;40:479-489.
22. Gotis-Graham I, Smith MD, Parker A, McNeil HP. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann Rheum Dis 1998;57:664-671.
23. Ramirez J, Celis R, Usategui A, et al. Immunopathologic characterization of ultrasound-defined synovitis in rheumatoid arthritis patients in clinical remission. Arthritis Res Ther 2016;18:74.
24. Woolley DE, Tetlow LC. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion. Arthritis Res Ther 2006;2:65-74.
25. Tetlow LC, Harper N, Dunningham T, Morris MA, Bertfield H, Woolley DE. Effects of induced mast cell activation on prostaglandin E and metalloproteinase production by rheumatoid synovial tissue in vitro. Ann Rheum Dis 1998;57:25-32.
26. Lee H, Kashiwakura J, Matsuda A, et al. Activation of human synovial mast cells from rheumatoid arthritis or osteoarthritis patients in response to aggregated IgG through Fcγ receptor I and Fcγ receptor II. Arthritis Rheum 2013;65:109-119.
27. Suurmond J, Rivellese F, Dorjee AL, et al. Toll-like recep-
tor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann Rheum Dis 2015;74:1915-1923.

28. Rivellese F, Suurmond J, Habets K, et al. Ability of interleukin-33- and immune complex-triggered activation of human mast cells to down-regulate monocyte-mediated immune responses. Arthritis Rheumatol 2015;67:2343-2353.

29. Martin CA, Carson SE, Kowalewski R, Bernstein D, Valentino M, Santi-Schwartz F. Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp/DC-mediated cross-priming. J Immunol 2003;171:5736-5742.

30. Midwood K, Sacre S, Piccinini AM, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009;15:774-780.

31. Gondokaryono SP, Ushio H, Niyonsaba F, et al. The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4. J Leukoc Biol 2007;82:657-665.

32. Okamura Y, Mishima S, Kashiwakura JI, et al. The dual regulation of substance P-mediated inflammation via human synovial mast cells in rheumatoid arthritis. Allergol Int 2017;66 Suppl 2:32-36.

33. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-10918.

34. Xu D, Jiang HR, Li Y, et al. IL-33 exacerbates autoantibody-induced arthritis. J Immunol 2010;184:2411-2419.

35. Kashiwakura J, Yanagisawa M, Lee H, et al. Interleukin-33 synergistically enhances immune complex-induced tumor necrosis factor alpha and interleukin-8 production in cultured human synovium-derived mast cells. Int Arch Allergy Immunol 2013;161 Suppl 2:32-36.

36. Binstadt BA, Patel PR, Alencar H, et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat Immunol 2006;7:28-34.

37. Bridges AJ, Malone DG, Jicinsky J, et al. Human synovial mast cell involvement in rheumatoid arthritis and osteoarthritis. Relationship to disease type, clinical activity, and rheumatoid arthritis. Arthritis Rheum 1991;34:1116-1124.

38. Nent E, Frommholz D, Gajda M, Brauer R, Illges H. Histamine 4 receptor plays an important role in auto-antibody-induced arthritis. Int Immunol 2013;25:437-443.

39. Kim KW, Kim BM, Lee KA, Lee SH, Firestein GS, Kim HR. Histamine and histamine H4 receptor promotes osteoclastogenesis in rheumatoid arthritis. Sci Rep 2017;7:1197.

40. Kronen J, Kortun A, Kemmler J, et al. Mast cells are critical regulators of bone fracture-induced inflammation and osteoclast formation and activity. J Bone Miner Res 2017;32:2411-2444.

41. Gruber BL, Schwartz LB, Ramamurthy NS, Irani AM, Marchese MJ. Activation of latent rheumatoid synovial collagenase by human mast cell tryptase. J Immunol 1988;140:3096-3092.

42. Shin K, Ngivroca PA, Crish J, et al. Mast cells contribute to autoimmune inflammatory arthritis via their tryptase/heparin complexes. J Immunol 2009;182:647-656.

43. McNeil HP, Shin K, Campbell IK, et al. The mouse mast cell-restricted tetramer-forming tryptases mouse mast cell protease 6 and mouse mast cell protease 7 are critical mediators in inflammatory arthritis. Arthritis Rheum 2008;58:3238-3246.

44. Deladai-Souza A, Ribeiro CM, Rolland C, et al. Effect of tryptase inhibition on joint inflammation: a pharmacological and lentivirus-mediated gene transfer study. Arthritis Res Ther 2017;19:124.

45. Zhao L, Yamaguchi Y, Ge X, Robinson WH, Morser J, Leung LLK. Chemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients. Arthritis Res Ther 2018;20:132.

46. Chu Y, Wang J, Zhou X. Mast cell chymase in synovial fluid of collagen-induced-arthritis rats regulates gelatinase release and promotes synovial fibroblasts proliferation via FAK/p21 signaling pathway. Biochem Biophys Res Commun 2019;514:336-343.

47. de Souza Junior DA, Santana AC, da Silva EZ, Oliver C, Jamur MC. The role of mast cell specific chymases and tryptases in tumor angiogenesis. Biomed Res Int 2015;2015:142359.

48. Norrby K. Mast cells and angiogenesis. APMIS 2002;110:355-371.

49. Hoxha M. A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. Adv Med Sci 2018;63:22-29.

50. Noack M, Miossec P. Selected cytokine pathways in rheumatoid arthritis. Semin Immunopathol 2017;39:369-383.

51. Mathis SP, Jala VR, Lee DM, Haribabu B. Nonredundant roles for leukotriene B4 receptors BLT1 and BLT2 in inflammatory arthritis. J Immunol 2016;185:3049-3056.
52. Miyahara N, Ohnishi H, Miyahara S, et al. Leukotriene B4 release from mast cells in IgE-mediated airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 2009;40:672-682.

53. Cho C, Nguyen A, Bryant KJ, O’Neill SG, McNeil HP. Prostaglandin D2 metabolites as a biomarker of in vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis. Immun Inflamm Dis 2015;4:64-69.

54. Sandler C, Lindstedt KA, Joutsiniemi S, et al. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. Inflamm Res 2007;56:230-239.

55. Nigrovic PA, Binstadt BA, Monach PA, et al. Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A 2007;104:2323-2330.

56. Hueber AJ, Asquith DL, Miller AM, et al. Mast cells express IL-17A in rheumatoid arthritis synovium. J Immunol 2016;196:3336-3340.

57. Kan J, Mishima S, Kashiwakura J, et al. Interleukin-17A expression in human synovial mast cells in rheumatoid arthritis and osteoarthritis. Allergol Int 2016;65 Suppl:S11-S16.

58. Guma M, Kashiwakura J, Crain B, et al. JNK1 controls mast cell degranulation and IL-1[alpha] production in inflammatory arthritis. Proc Natl Acad Sci U S A 2010;107:22122-22127.

59. van der Velden D, Lagraauw HM, Wezel A, et al. Mast cell depletion in the preclinical phase of collagen-induced arthritis reduces clinical outcome by lowering the inflammatory cytokine profile. Arthritis Res Ther 2016;18:138.

60. Juurikivi A, Sandler C, Lindstedt KA, et al. Inhibition of c-kit tyrosine kinase by imatinib mesylate induces apoptosis in mast cells in rheumatoid synovia: a potential approach to the treatment of arthritis. Ann Rheum Dis 2005;64:1126-1131.

61. Shioj N, Kovanen PT, Eklund KK, et al. The anti-allergic compound tranilast attenuates inflammation and inhibits bone destruction in collagen-induced arthritis in mice. Br J Pharmacol 2010;159:626-635.

62. Gri G, Frossi B, D’Inca F, et al. Mast cell: an emerging partner in immune interaction. Front Immunol 2012;3:120.

63. Palm AK, Garcia-Faroldi G, Lundberg M, Pejler G, Klean au S. Activated mast cells promote differentiation of B cells into effector cells. Sci Rep 2016;6:20531.

64. Stelekat E, Bahri R, D’Orlando O, et al. Mast cell-medi ated antigen presentation regulates CD8+ T cell effector functions. Immunity 2009;31:663-676.

65. Kambayashi T, Allenspach EJ, Chang JT, et al. Inducible MHC class II expression by mast cells supports effector and regulatory T cell activation. J Immunol 2009;182:4868-4869.

66. Suurmond J, van Heemst J, van Heiningen J, et al. Communication between human mast cells and CD4+ T cells through antigen-dependent interactions. Eur J Immunol 2013;43:1758-1768.

67. Gaudenzi N, Laurent C, Valitutti S, Espinosa E. Human mast cells drive memory CD4+ T cells toward an inflammatory IL-22+ phenotype. J Allergy Clin Immunol 2013;131:1460-1467.

68. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol 2005;6:974-981.

69. Nakae S, Suto H, Kakurai M, Sedgwick JD, Tsai M, Galli SJ. Mast cells enhance T cell activation: Importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 2005;102:6467-6472.

70. Gruber BL, Marchese MJ, Suzuki K, et al. Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest 1989;84:1657-1662.

71. Tetlow LC, Woolley DE. Mast cells, cytokines, and metalloproteinases at the rheumatoid lesion: dual immunological studies. Ann Rheum Dis 1995;54:866-903.

72. Sawamukai N, Yukawa S, Saito K, Nakayamada S, Kambayashi T, Tanaka Y. Mast cell-derived tryptase inhibits apoptosis of human rheumatoid synovial fibroblasts via rho-mediated signaling. Arthritis Rheum 2010;62:932-939.

73. Galli SJ, Grimbaldeston M, Tsai M. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 2008;8:478-486.

74. Rossini M, Viapiana O, Zanoni G, et al. Serum levels of tryptase suggest that mast cells might have an antiinflammatory role in rheumatoid arthritis: comment on the article by Rivellese et al. Arthritis Rheumatol 2016;68:769-770.

75. Rivellese F, de Paulis A, Marone G, Pitzalis C, Toes RE. Reply. Arthritis Rheumatol 2016;68:769-770.

76. Magnusson PE, Pejler G, Kleinau S, Abrink M. Mast cell chymase contributes to the antibody response and the severity of autoimmune arthritis. FASEB J 2009;23:875-882.

77. Heger K, Fierens K, Vahl JC, et al. A2o-deficient mast cells
exacerbate inflammatory responses in vivo. PLoS Biol 2014;12:e1001762.

78. Lee DM, Friend DS, Gurish MF, Benoist C, Mathis D, Brenner MB. Mast cells: a cellular link between autoantibodies and inflammatory arthritis. Science 2002;297:1689-1692.

79. Kneilling M, Hultner L, Pichler BJ, et al. Targeted mast cell silencing protects against joint destruction and angiogenesis in experimental arthritis in mice. Arthritis Rheum 2007;56:1806-1816.

80. Reber LL, Marichal T, Galli SJ. New models for analyzing mast cell functions in vivo. Trends Immunol 2012;33:613-625.

81. Schubert N, Dudeck J, Liu P, et al. Mast cell promotion of T cell-driven antigen-induced arthritis despite being dispensable for antibody-induced arthritis in which T cells are bypassed. Arthritis Rheumatol 2015;67:903-913.

82. Zhou JS, Xing W, Friend DS, Austen KF, Katz HR. Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis. J Exp Med 2007;204:2797-2802.

83. Pitman N, Asquith DL, Murphy G, Liew FY, McInnes IB. Collagen-induced arthritis is not impaired in mast cell-deficient mice. Ann Rheum Dis 2011;70:1170-1171.

84. Grimbaldeston MA, Chen CC, Piliponsky AM, Tsai M, Tam SY, Galli SJ. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005;167:835-848.

85. Feyerabend TB, Weiser A, Tietz A, et al. Cre-mediated cell ablation contests mast cell contribution in models of antibody- and T cell-mediated autoimmunity. Immunity 2011;35:832-844.

86. Bluett J, Barton A. Precision medicine in rheumatoid arthritis. Rheum Dis Clin North Am 2017;43:377-387.

87. Mukai K, Tsai M, Saito H, Galli SJ. Mast cells as sources of cytokines, chemokines, and growth factors. Immunol Rev 2018;282:121-150.

88. Suurmond J, Dorjee AL, Huizinga TW, Toes RE. Human mast cells costimulate T cells through a CD28-independent interaction. Eur J Immunol 2016;46:1132-1141.